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summary
Sjögren’s syndrome (SjS) is an autoimmune disease that affects the salivary and lacrimal glands, but it can 
also have extra-glandular manifestations. Although pain has not yet been fully studied and characterized, it is a 
symptom that can be often found in patients with SjS, who mainly complain of neuropathic pain, followed by 
nociceptive pain. The latter when combined with widespread dysfunctional symptoms is defined fibromyalgia. 
The aim of this work is to analyze the scientific literature on the presence of pain in patients with primary 
Sjögren’s syndrome.
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n	 INTRODUCTION
Sjögren’s syndrome (SjS) is a systemic autoimmune disease that affects the 
exocrine glands, in particular the salivary 
and lacrimal glands (sicca syndrome), but 
it can also have extra-glandular manifes-
tations. The SjS has a prevalence between 
0.2 and 3% in the general population, with 
a male:female ratio of 1:9 (1). Along with 
the typical manifestations of the disease, 
including oral and ocular dryness, many 
patients with SjS have peripheral neurop-
athy and other neurological disorders (2-
4). Another complication associated with 
SjS that occurs in a variable percentage of 
patients (4-5%), is the B-cell lymphoma 
(1, 5, 6). 
The diagnostic criteria of SjS (7) focus on 
the relevance of oral and ocular symptoms, 
the involvement of the salivary glands in-
vestigated by means of a biopsy and a sia-
lography (lymphocytic infiltration) and the 
presence of autoantibodies to Ro-SSA and/
or La-SSB. 
Pain does not currently fall under the clas-
sification criteria of the disease. However, 
since it is frequently reported by patients, 
the aim of this paper is to review the litera-
ture on this symptom which is widespread 
and often debilitates SjS patients and has 
also important implications in the choice of 
therapy.
Neuropathic pain in Sjögren’s syndrome
Only a limited number of studies of pain in 
SjS can be found in the literature.
Neuropathic pain seems to be very fre-
quent and significant in SjS (8) but in the 
literature we found very discordant data 
concerning frequency, which ranges from 
less than 2 (9) to over 60% (10). These dis-
crepancies can be attributed to several fac-
tors, such as differences in the diagnostic 
criteria, the design and the methodology of 
the studies, which are mostly retrospective 
and with a limited sample of patients, and 
the differences in the definition of periph-
eral neuropathy, which does not always 
include clinical and electrophysiological 
objective tests. An interesting review based 
on a large cohort of patients, published by 
Pavlakis et al. (11), studied the neuropathic 
manifestations in SjS. The authors under-
lined that only 15 out of 509 SjS patients 
met the diagnostic criteria for small fiber 
peripheral neuropathy as well as axonal 
polyneuropathy. The skin biopsies of pa-
tients with small fiber neuropathy showed 
a characteristic hypodensity of fibers and 
a significant reduction in the number of 
small fibers. However, the pathogenesis of 
this neuropathy is still unclear. Infiltrates of 
T cells, a common finding in the salivary 
glands of SjS patients, were also associated 
with vasculitis (12). Although vasculitis is 
a rare event in SjS (13), the inflammatory 
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infiltration of the vessel walls leads to the 
destruction of the endothelial cells, which 
appears to correlate with the presence of 
mononeuropathy and polyneuropathy (14, 
15). In a paper published by Ramos-Casals 
et al. (16), 16% of 558 patients with SjS 
showed a cutaneous involvement, which 
in 58% of these cases was of vasculitic 
origin. Although the pathogenic role of T 
cells in the development of neuropathy re-
mains still unclear, it appears to be related 
to the production of interleukins (IL), in 
particular IL-6 and IL8, as highlighted by 
a recent work that evaluated the high pres-
ence of these cytokines in skin biopsies of 
patients with small fiber neuropathy (17). 
Another suggested pathogenic mechanism 
of neuropathy in SjS seems to be related to 
B lymphocytes. In particular some autoan-
tibodies are thought to be related to neu-
ropathy, such as antibodies versus GW/P 
(18), a-fodrin (19) and anti-muscarinic 
acetylcholine type III receptor (20). These 
antibodies, however, are nonspecific, and 
the correlation with neuropathies is not al-
ways confirmed.
In a recent paper published by Segal et al. 
(21), the authors evaluated the presence of 
neuropathic pain, comorbidity, and quality 
of life (QoL) in 108 patients with SjS. In 
particular, they assessed the influence of 
seropositivity (anti Ro/SSA La/SSB) on 
the clinical features, the outcome of the 
disease and the prevalence of neuropathic 
and chronic pain. The authors also evalu-
ated the presence of psychiatric comorbid-
ity in these patients. The results show that 
pain is a symptom reported by both groups 
of patients, namely 65% in the seropositive 
group and 75% in the seronegative group. 
A significant difference was identified in 
the intensity of pain, which was found to be 
higher in the group of seronegative patients. 
Although other symptoms, such as fatigue, 
anxiety and depression were not statisti-
cally significant in the groups of seroposi-
tive and seronegative patients, they affect 
a high percentage of patients. This study 
also shows that pain and the impairment of 
physical skills were more severe in sero-
negative patients and confirms that chronic 
pain affects a high percentage of patients. 
However, the presence of neuropathic pain 
can often be underestimated, as it is mainly 
assessed by patient’s interviews, using ver-
bal descriptors, thus potentially leading to 
incorrect evaluations. From an analysis of 
the literature, it emerged that a high per-
centage of SjS patients are also affected by 
a comorbidity, i.e. fibromyalgia (FM) (22, 
23), which could explain the high percent-
age of chronic pain in these patients (24). 
Widespread pain in Sjögren’s syndrome
Widespread pain is a symptom reported by 
72% of SjS patients (25). In addition, sev-
eral studies report a high incidence of fi-
bromyalgia in SjS, as shown in (25-27). An 
interesting work published by Iannuccelli 
et al. (28) wonders whether pain in SjS is 
a result of inflammation or comorbid fibro-
myalgia. In a cohort of 50 SjS patients, the 
authors evaluated the presence of extreme-
ly debilitating symptoms, such as fatigue, 
widespread pain, QoL by administering the 
health assessment questionnaire, and the 
fibromyalgia impact questionnaire (FIQ). 
Anxiety and depression were assessed on 
the basis of the Zung anxiety and depres-
sion scales. The presence of FM was as-
sessed also by examining the tender points. 
The most interesting result is the high per-
centage of SjS patients who report fatigue 
(88%) and pain (90%), even though visual 
analogue scores, pain and fatigue were not 
statistically significant with respect to the 
patients with systemic lupus erythemato-
sus (SLE). However the presence of fibro-
Table I - Percentage of fibromyalgia on Sjögren’s syndrome.
author year of publication Number of patients Percentage of Fm
Ostuni et al. (26) 2002 100 22%
Dohrenbusch et al. (25) 1996 38 44%
Bonafede et al. (27) 1995 72 11%
FM, fibromyalgia.
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myalgia was significantly lower in the SjS 
group compared with the SLE group (9/50 
vs 16/50). Figure 1 shows the data about 
tender points, fatigue, pain and FIQ in the 
group of patients with co-morbid fibromy-
algia versus those with the connective tis-
sue disease only. Remarkably, the percent-
age of patients that reported fatigue and 
pain was higher in patients with SjS, even 
in the group of patients without FM. The 
authors concluded that fibromyalgia con-
tributes more significantly to the presence 
of pain in SLE patients than in SjS patients, 
suggesting that the causes for fatigue and 
widespread pain are different in these two 
connective tissue diseases. 
In a recent paper the psychological aspects 
of catastrophizing were investigated in 
patients with SjS (29). The authors evalu-
ated various aspects of the disease through 
questionnaires, which included questions 
on pain, fatigue and catastrophizing, and 
explored the influence of each variable on 
pain, using a linear regression curve. The 
results show that catastrophizing is highly 
predictive of pain, fatigue, anxiety and de-
pression, independently from the immuno-
logical status, therefore an approach aimed 
at reducing this psychological symptom 
may be useful to improve the QoL of pa-
tients with SjS.
n	 CONCLUSIONS
Although SjS patients frequently complain 
of pain, this symptom is not included in the 
diagnostic criteria of the disease. However, 
both clinical experience and the limited 
scientific literature available show a corre-
lation between pain and SjS. Neuropathic 
pain, especially when small fibers are in-
volved, seems to be the most frequent, 
although its pathogenic mechanisms have 
not yet been clarified. Furthermore, the 
difficulty in classifying the type of neuro-
pathic pain may lead to an underestimation 
of this symptom.
The inflammatory pain related to the au-
toimmune origin of the disease mostly 
involves the joints and manifests itself as 
arthralgia/arthritis pain, and is therefore a 
more common symptom.
SS patients also often complain of wide-
spread pain, which seems to be caused by 
comorbid fibromyalgia and must be clearly 
diagnosed to administer a proper treatment 
and avoid overtreatment. Finally, affective 
and mood disorders are often present in 
SjS and catastrophizing adversely affects 
the perception of pain and quality of life of 
the patient.
In conclusion, although the classification 
criteria do not include an assessment of 
Figure 1 - Fibromyalgia was diagnosed in a higher percentage of systemic lupus erythemato-
sus patients versus Sjögren’s syndrome patients (32% vs 18%, P=0.022).
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pain, a correct approach to SjS patients 
should take it into account, especially 
when it is not due to an inflammatory or 
neuropathic mechanism, to implement an 
adequate therapeutic strategy to improve 
their quality of life.
n	 RefeReNCeS
1. Reksten TR, Jonsson MV. Sjögren’s syn-
drome: an update on epidemiology and current 
insights on pathophysiology. Oral Maxillofac 
Surg Clin North Am. 2014; 26: 1-12.
2. Pavlakis PP, Alexopoulos H, Kosmidis ML, 
Mamali I, Moutsopoulos HM, Tzioufas AG, et 
al. Peripheral neuropathies in Sjögren’s syn-
drome: a critical update on clinical features 
and pathogenetic mechanisms. J Autoimmun. 
2012; 39: 27-33.
3. Sène D, Jallouli M, Lefaucheur JP, Saadoun 
D, Costedoat-Chalumeau N, Maisonobe T, et 
al. Peripheral neuropathies associated with 
primary Sjögren syndrome: immunologic pro-
files of nonataxic sensory neuropathy and sen-
sorimotor neuropathy. Medicine (Baltimore). 
2011; 90: 133-8.
4. Chai J, Herrmann D, Stanton M, Barbano R, 
Logigian E. Painful small-fiber neuropathy 
in Sjögren syndrome. Neurology. 2005; 65: 
925-7.
5. Solans-Laque R, Lopez-Hernandez A, Bosch-
Gil J, Palacios A, Campillo M, Vilardell-Tarres 
M. Risk, predictors, and clinical character-
istics of lymphoma development in primary 
Sjögren’s syndrome. Semin Arthritis Rheum. 
2011; 41: 415-23.
6. Bartoloni E, Alunno A, Gerli R. Primary 
Sjögren’s syndrome as paraneoplastic disor-
der: a case report. Clin Exp Rheumatol. 2012; 
30: 454.
7. Vitali C, Bombardieri S, Jonsson R, Moutso-
poulos HM, Alexander EL, Carsons SE, et al. 
Classification criteria for Sjögren’s syndrome: 
a revised version of the European criteria pro-
posed by the American-European Consensus 
Group. Ann Rheum Dis. 2002; 61: 544-8.
8. Brito-Zerón P, Akasbi M, Bosch X, Bové A, 
Pérez-De-Lis M, Diaz-Lagares C, et al. Clas-
sification and characterisation of peripheral 
neuropathies in 102 patients with primary 
Sjögren’s syndrome. Clin Exp Rheumatol. 
2013; 31: 103-10.
9. Pavlakis PP, Alexopoulos H, Kosmidis ML, 
Stamboulis E, Routsias JG, Tzartos SJ, et al. 
Peripheral neuropathies in Sjögren syndrome: 
a new reappraisal. J Neurol Neurosurg Psy-
chiatry. 2011; 82: 798-802. 
10. Lopate G, Pestronk A, Al-Lozi M, Lynch T, 
Florence J, Miller T, Levine T, et al. Peripheral 
neuropathy in an outpatient cohort of patients 
with Sjögren’s syndrome. Muscle Nerve. 
2006; 33: 672-6. 
11. Pavlakis PP, Alexopoulos H, Kosmidis ML, 
Mamali I, Moutsopoulos HM, Tzioufas AG, et 
al. Peripheral neuropathies in Sjögren’s syn-
drome: a critical update on clinical features 
and pathogenetic mechanisms. J Autoimmun. 
2012; 39: 27-33. 
12. Gorson KC. Vasculitic neuropathies: an up-
date. Neurologist. 2007; 13: 12-9.
13. Ramos-Casals M, Solans R, Rosas J, Camps 
MT, Gil A, Del Pino-Montes J, et al. Primary 
Sjögren syndrome in Spain: clinical and im-
munologic expression in 1010 patients. Medi-
cine (Baltimore). 2008; 87: 210-9. 
14. Terrier B, Lacroix C, Guillevin L, Hatron PY, 
Dhote R, Maillot F, et al. Diagnostic and prog-
nostic relevance of neuromuscular biopsy in 
primary Sjögren’s syndrome-related neuropa-
thy. Arthritis Rheum. 2007; 57: 1520-9.
15. Sène D, Jallouli M, Lefaucheur JP, Saadoun 
D, Costedoat-Chalumeau N, Maisonobe T, et 
al. Peripheral neuropathies associated with 
primary Sjögren syndrome: immunologic pro-
files of nonataxic sensory neuropathy and sen-
sorimotor neuropathy. Medicine (Baltimore). 
2011; 90: 133-8. 
16. Ramos-Casals M, Anaya JM, García-
Carrasco M, Rosas J, Bové A, Claver G, et 
al. Cutaneous vasculitis in primary Sjögren 
syndrome: classification and clinical signifi-
cance of 52 patients. Medicine (Baltimore). 
2004; 83: 96-106. 
17. Uçeyler N, Kafke W, Riediger N, He L, Ne-
cula G, Toyka KV, et al. Elevated proinflam-
matory cytokine expression in affected skin in 
small fiber neuropathy. Neurology. 2010; 74: 
1806-13.
18. Bhanji RA, Eystathioy T, Chan EK, Bloch 
DB, Fritzler MJ. Clinical and serological fea-
tures of patients with autoantibodies to GW/P 
bodies. Clin Immunol. 2007; 125: 247-56.
19. Mori K, Iijima M, Koike H, Hattori N, Tanaka 
F, Watanabe H, et al. The wide spectrum of 
clinical manifestations in Sjögren’s syndrome-
associated neuropathy. Brain. 2005; 128: 
2518-34.
20. Dawson L, Tobin A, Smith P, Gordon T. Anti-
muscarinic antibodies in Sjögren’s syndrome: 
where are we, and where are we going? Arthri-
tis Rheum. 2005; 52: 2984-95.
21. Segal BM, Pogatchnik B, Henn L, Rudser K, 
Sivils KM. Pain severity and neuropathic pain 
symptoms in primary Sjögren’s syndrome: a 
comparison study of seropositive and seroneg-
ative Sjögren’s syndrome patients. Arthritis 
Care Res (Hoboken). 2013; 65: 1291-8. 
22. Giles I, Isenberg D. Fatigue in primary 
Sjögren’s syndrome: is there a link with the 
fibromyalgia syndrome? Ann Rheum Dis. 
2000; 59: 875-8.
No
n-
co
me
rci
al 
us
e o
nly
Reumatismo 1/2014 43
reviewPain in Sjögren’s syndrome
23. Giacomelli C, Sernissi F, Sarzi-Puttini P, Di 
Franco M, Atzeni F, Bazzichi L. Fibromyal-
gia: a critical digest of the recent literature. 
Clin Exp Rheumatol. 2013; 31: S153-7.
24. Koroschetz R, Rehm SE, Gockel U, Brosz M, 
Freynhagen F, Tolle TR, et al. Fibromyalgia 
and neuropathic pain: differences and simi-
larities. A comparison of 3057 patients with 
diabetic painful neuropathy and fibromyalgia. 
BMC Neurol. 2011; 11: 55.
25. Dohrenbusch R, Grüterich M, Genth E. Fibro-
myalgia and Sjögren syndrome--clinical and 
methodological aspects. Z Rheumatol. 1996; 
55: 19-27.
26. Ostuni P, Botsios C, Sfriso P, Bertagnin A, 
Cozzi F, Doria A, Todesco S. Prevalence and 
clinical features of fibromyalgia in systemic 
lupus erythematosus, systemic sclerosis and 
Sjögren’s syndrome. Minerva Med. 2002; 93 
(3): 203-9.
27. Bonafede RP, Downey DC, Bennett RM. An 
association of fibromyalgia with primary 
Sjögren’s syndrome: a prospective study of 72 
patients. J Rheumatol. 1995; 22 (1): 133-6.
28. Iannuccelli C, Spinelli FR, Guzzo MP, Priori 
R, Conti F, Ceccarelli F, et al. Fatigue and 
widespread pain in systemic lupus erythe-
matosus and Sjögren’s syndrome: symptoms 
of the inflammatory disease or associated fi-
bromyalgia? Clin Exp Rheumatol. 2012; 30: 
117-21.
29. Segal B, Pogatchnik B, Rhodus N, Sivils 
KM, McElvain G, Solid C. Pain in primary 
Sjögren’s syndrome: the role of catastrophiz-
ing and negative illness perceptions. Scand J 
Rheumatol. 2014. [Epub ahead of print].
No
n-
co
mm
er
cia
l u
se
 on
ly
